Cross-reactivity in β-Lactam Allergy.
Zagursky RJ, Pichichero ME.
J Allergy Clin Immunol Pract · review; journal article · DOI 10.1016/j.jaip.2017.08.027 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för cefpodoxime. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
9 träffarResistance of Streptococcus pneumoniae isolated from Lebanese patients between 2005 and 2009.
Daoud Z, Kourani M, Saab R, Nader MA, Hajjar M.
Rev Esp Quimioter · multicenter study; journal articleDose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors.
McGregor LM, Stewart CF, Crews KR, Tagen M, Wozniak A, Wu J, McCarville MB, Navid F, Santana VM, Houghton PJ, Furman WL, Rodriguez-Galindo C.
Pediatr Blood Cancer · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1002/pbc.23075Pharmacokinetics of cefpodoxime in plasma and subcutaneous fluid following oral administration of cefpodoxime proxetil in male beagle dogs.
Kumar V, Madabushi R, Lucchesi MB, Derendorf H.
J Vet Pharmacol Ther · research support, non-u.s. gov't; journal article · DOI 10.1111/j.1365-2885.2010.01198.x[Acceptability, compliance and schedule of administration of oral antibiotics in outpatient children].
Wollner A, Lécuyer A, De La Rocque F, Sedletzki G, Derkx V, Boucherat M, Elbez A, Gelbert-Baudino N, Levy C, Corrard F, Cohen R.
Arch Pediatr · research support, non-u.s. gov't; journal article; english abstract; observational study · DOI 10.1016/j.arcped.2011.02.010Cefpodoxime 10 μg disc screening test for detection of Neisseria gonorrhoeae with mosaic PBP2 and decreased susceptibility to extended-spectrum cephalosporins for public health purposes.
Limnios A, Tapsall J, Kahlmeter J, Hogan T, Ray S, Lam A, Unemo M.
APMIS · research support, non-u.s. gov't; journal article · DOI 10.1111/j.1600-0463.2011.02729.xClinical effectiveness and safety of gemifloxacin versus cefpodoxime in acute exacerbation of chronic bronchitis: A randomized, controlled trial.
Chatterjee S, Biswas T, Dutta A, Sengupta G, Mitra A, Kundu S.
Indian J Pharmacol · research-article; journal article · DOI 10.4103/0253-7613.75667Enhancement of bioavailability of cefpodoxime proxetil using different polymeric microparticles.
Khan F, Katara R, Ramteke S.
AAPS PharmSciTech · research-article; journal article · DOI 10.1208/s12249-010-9505-xPhysicochemical and pharmacokinetic characterization of a spray-dried cefpodoxime proxetil nanosuspension.
Gao Y, Qian S, Zhang J.
Chem Pharm Bull (Tokyo) · research support, non-u.s. gov't; journal article · DOI 10.1248/cpb.58.912